Call Now Open
2026 Oxford-Harrington Rare Disease Scholar Award
January 29, 2026
“We embed industry expertise directly into academia through our Scholar Award program, which provides a mini‑biotech/pharma team to each Oxford‑Harrington Scholar we support,” says Matthew Anderson, Co‑Director of the Oxford‑Harrington Rare Disease Centre.
Each Scholar receives drug development, commercial strategy, and business development support—an approach designed to move discoveries to patients faster.
At the Oxford-Harrington Rare Disease Centre (OHC), this model is redefining how rare disease medicines are developed. By pairing University of Oxford’s deep research strengths with Harrington Discovery Institute at University Hospitals translational expertise, the OHC is creating a clear path from academic discovery to clinical readiness.
The results are already taking shape. In 2025, the Centre announced its second cohort of 10 Rare Disease Scholars, advancing treatments for neurological, immune, metabolic, and cancer‑related conditions using gene therapies, RNA‑based therapeutics, enzyme replacement strategies, and targeted medicines.
Harrington Discovery Institute is proud to power this mission—bringing industry‑grade development capabilities directly to academic innovators and accelerating the creation of medicines for the 95% of rare diseases still without approved treatments.
Read the full article in PharmaSource
Neuroscience, Rare/Orphan
University Hospitals - Cleveland
Harrington Investigators